A Study to Assess the Drug-drug Interaction of BMS-963272 and Rosuvastatin

Completed · Phase 1

Conditions studied: Healthy Participants

In brief

Phase 1 study that assesses the effect of BMS-963272 on exposure of rosuvastatin in healthy participants

Key facts

Study ID

NCT04124003

Run by

Bristol-Myers Squibb

People needed

28

Starts

2019-10-08

Expected to finish

2020-01-03

Last updated by the study team

2020-03-10

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy participants, as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
• Women must not be of childbearing potential (WNOCBP)
• Women and men must agree to follow instructions for methods of contraception

You may not qualify if…

• Any significant acute or chronic medical condition that presents a potential risk to the participant and/or may compromise the objectives of the study.
• Any major surgery within 4 weeks of study drug administration
• Any blood transfusion or donation of blood to a blood bank or in a clinical study within 4 weeks of study drug administration
• Previous treatment with BMS-963272
• Participants who smoke, as well as, those who have stopped smoking less than 6 months prior to day 1
• Other protocol-defined inclusion/exclusion criteria could apply

Where it is running

• PRA Health Sciences - Salt Lake — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.